Kairos Pharma, Ltd.SEC Filings
|
|
All SEC filings by Kairos Pharma, Ltd. (KAPA) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 12, 2026 | |
| ARS | Annual report to shareholders | May 22, 2026 | ||
| 10-Q | Quarterly report | View Diff | May 13, 2026 | |
| 10-K | Annual report | View Diff | Mar 31, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 12, 2025 | |
| 10-K/A | Annual report | Jul 28, 2025 | ||
| 10-Q | Quarterly report | View Diff | May 14, 2025 | |
| 10-K/A | Annual report | Apr 28, 2025 | ||
| 10-K | Annual report | Apr 15, 2025 |
Events
| 8-K | Kairos Pharma Announces 1-For-7 Reverse Stock Split | Aug 21, 2026 | ||
| 8-K | Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance Xofigo Activity in Metastatic Prostate Cancer | Jul 22, 2026 | ||
| 8-K | Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105in Egfr-Mutated Lung Cancer Patients | Jul 15, 2026 | ||
| 8-K | Current report | Jun 30, 2026 | ||
| 8-K | Current report | Jun 4, 2026 | ||
| 8-K | Other Events | May 18, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | Mar 2, 2026 | ||
| 8-K | Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets From Celyn Therapeutics | Feb 26, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Oct 15, 2025 | ||
| 8-K | Kairos Pharma to Present Positive Safety and Efficacy Data From Phase 2 Prostate Cancer Trial at Esmo 2025 | Oct 7, 2025 |
Registrations and Prospectuses
| 424B3 | Prospectus supplement | Apr 1, 2026 | ||
| 424B3 | Prospectus supplement | Apr 1, 2026 | ||
| S-3 | Shelf registration | Jan 12, 2026 | ||
| 424B3 | Prospectus supplement | Aug 19, 2025 | ||
| 424B3 | Prospectus supplement | Apr 25, 2025 | ||
| S-1 | IPO registration | View Diff | Apr 21, 2025 | |
| 424B3 | Prospectus supplement | Feb 5, 2025 | ||
| S-1 | IPO registration | View Diff | Jan 29, 2025 | |
| D | $8.75 Mm in Options / Securities to Be Acquired, Sold $3.50 Mm, 1 Investor | Jan 28, 2025 | ||
| DRS | Draft registration statement | Jan 3, 2025 |
Proxies
| DEFA14A | Additional proxy soliciting materials | May 26, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | May 22, 2026 | |
| PRE 14A | Preliminary proxy | May 11, 2026 | ||
| DEFR14A | Revised proxy | May 16, 2025 | ||
| PRER14A | Preliminary revised proxy | May 6, 2025 | ||
| DEF 14A | Definitive proxy | Apr 30, 2025 | ||
| DEF 14C | Information statement | Feb 10, 2025 | ||
| PRE 14C | Preliminary information | Jan 29, 2025 |
Other
| EFFECT | Notice of effectiveness | Jan 26, 2026 | ||
| CORRESP | Correspondence with SEC | Jan 21, 2026 | ||
| UPLOAD | Letter from SEC | Jan 15, 2026 | ||
| EFFECT | Notice of effectiveness | Apr 25, 2025 | ||
| CORRESP | Correspondence with SEC | Apr 22, 2025 | ||
| EFFECT | Notice of effectiveness | Feb 5, 2025 | ||
| UPLOAD | Letter from SEC | Jan 31, 2025 | ||
| CORRESP | Correspondence with SEC | Jan 31, 2025 | ||
| UPLOAD | Letter from SEC | Jan 6, 2025 | ||
| EFFECT | Notice of effectiveness | Sep 17, 2024 |
Ownership
| 4 | Neil Bhowmick | Dec 30, 2025 | ||
| 4 | Hyun W. Bae | Dec 23, 2025 | ||
| 4 | Ramachandran Murali | Nov 26, 2025 | ||
| 4 | Hansoo Michael Keyoung | Nov 26, 2025 | ||
| 4 | Rahul Singhvi | Nov 26, 2025 | ||
| 4 | Doug Samuelson | Nov 26, 2025 | ||
| 4 | John S Yu | Nov 26, 2025 | ||
| SC 13G/A | Beneficial ownership report | Aug 14, 2025 | ||
| SC 13G | Kairos Pharma, Ltd. | May 15, 2025 | ||
| 3 | Rahul Singhvi | Apr 30, 2025 |